Why this ASX cannabis share is shooting 15% higher today

The Medlab Clinical Ltd (ASX:MDC) share price is shooting higher on Monday despite the market selloff. Here's why this cannabis share is on a high…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The market may be sinking lower again on Monday, but that hasn't stopped the Medlab Clinical Ltd (ASX: MDC) share price from charging higher.

The cannabis-focused biotech company's shares are up 15.5% to 26 cents in morning trade.

Why is the Medlab share price charging higher?

Investors have been buying Medlab's shares this morning following the release of an independent review of its NanaBis advanced cancer pain trial conducted at the Royal North Shore Hospital (RNSH).

The clinical trial was a Single Ascending Dose (SAD), Multiple Ascending Dose (MAD) investigation into pain management of patients with metastatic cancers.

According to the release, the trial met its primary endpoints and found that NanaBis is tolerable, efficacious, fast acting, and delivered improvements in quality of life measures. This was particularly the case in role and emotional functioning and insomnia.

In addition to this, secondary endpoints were met. This includes a meaningful pain reduction and significantly less morphine milliequivalent of dispensed opioid analgesics prescribed for breast or prostate cancers with bone metastasis.

Management believes this was a robust trial that has delivered strong results and allows it to focus on Phase 3 designs.

Dr Sean Hall, CEO of Medlab, advised, "With a strong trial design, that involved a professional and strong clinical trial team and collaborators, today we have primary evidence that NanaBis is safe, tolerable and provided a significant benefit in managing pain associated with metastatic cancers."

"There were a number of notable secondary gains, one of the biggest worth mentioning was a drastic reduction of breakthrough medication used by those patients with breast or prostate cancers with bone METs."

Dr Hall concluded: "We can confidently argue, NanaBis has a strong indication for use in pain management and is a compelling therapy for this patient group."

It is still very early days, but there is a potentially big opportunity for the product if everything goes to plan. The company notes that metastatic breast or prostate cancers have a high unmet need, with conservative 2017 numbers suggesting 600,000 patients in USA, Canada, Europe, and Australia.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Rising share price chart.
Share Gainers

Why Core Lithium, Goodman, GQG, and Macquarie shares are pushing higher today

These shares are starting the week in a positive fashion. But why?

Read more »

Happy woman working on a laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a pleasant end to the trading week for investors this Friday.

Read more »

A happy investor sits at his desk in front of his laptop and does the mexican wave with his arms to celebrate the returns from his ASX dividend shares
Share Gainers

Why Chrysos, GQG Partners, Macquarie, and Webjet shares are storming higher today

These shares are ending the week on a positive note. But why?

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Share Gainers

The top 3 ASX 200 trades since the Liberation Day dip

These companies are up at least 35% in just over a month.

Read more »

A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
Share Gainers

Boss Energy shares have rocketed 90% in a month. Here's why

The massive rally in Boss Energy shares will be painful to the host of short sellers betting against the uranium…

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors sent the market higher once again today.

Read more »

Rising gold share price represented by a green arrow on piles of gold block.
Gold

3 reasons to buy this surging ASX All Ords gold stock today

The ASX All Ords gold stock has doubled investors’ money in 12 months, and this leading expert forecasts more outperformance…

Read more »

Two colleagues at work looking at a tablet and smiling at a rising share price.
Share Gainers

Why Generation Development, Orica, Pro Medicus, and Zip shares are storming higher today

These shares are having a strong session on Thursday. But why?

Read more »